{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:25:44Z","timestamp":1789071944243,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Thyroid cancer is one of the most common endocrine neoplasms. Treatment methods include surgical resection, radioactive iodine therapy, inhibition of thyroid-stimulating hormone, and inhibition of kinase-based target therapies. These treatments induced adverse effects. Lithospermum officinale possesses antioxidant, anticancer, burn-healing, and anti-inflammatory activities, and Shikonin is the main ingredient. Antithyroid cancer studies of Shikonin discovered that it inhibited thyroid cancer cell migration and invasion by suppressing the epithelial\u2013mesenchymal transition; induced cell cycle arrest; induced DNA damage and apoptosis by producing excessive reactive oxygen species; upregulated Bax; increased the stability of p53; decreased the expression of Mdm2; downregulated Slug and MMP-2, MMP-9, and MMP-14; repressed the phosphorylation of Erk and Akt; activated the p16\/retinoblastoma protein pathway, leading to apoptosis; suppressed the expression of DNMT1; reduced the PTEN gene methylation; increased the expression of PTEN, leading to the inhibition of migration; increased LC3-II to induce autophagy and apoptosis of medullary thyroid carcinoma; and upregulated \u03b2II-tubulin in the cell to produce less resistance to cisplatin and paclitaxel, without cross-resistance to other anticancer agents. In vivo studies showed that it is safe in Sprague\u2013Dawley rats, Beagle dogs, and nude mice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1874467217666230904104414","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T01:48:50Z","timestamp":1693964930000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Research Progress of the Molecular Mechanism of Antithyroid Cancer Activity\nof Shikonin"],"prefix":"10.1016","volume":"17","author":[{"given":"Chunguang","family":"Sun","sequence":"first","affiliation":[{"name":"International Education College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial\nQianfoshan Hospital, Jinan, Shandong, 250024, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1089\/thy.2016.0100","volume":"26","author":"Wiltshire J. J.","year":"2016","unstructured":"Wiltshire J. J.; Drake T. M.; Uttley L.; Balasubramanian S. P.; Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid  2016,26(11),1541-1552","journal-title":"Thyroid"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.21037\/jtd.2019.08.37","volume":"12","author":"Bonjoc K.J.","year":"2020","unstructured":"Bonjoc K.J.; Young H.; Warner S.; Gernon T.; Maghami E.; Chaudhry A.; Thyroid cancer diagnosis in the era of precision imaging. J Thorac Dis  2020,12(9),5128-5139","journal-title":"J Thorac Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.path.2019.08.002","volume":"12","author":"Haroon Al Rasheed M.R.","year":"2019","unstructured":"Haroon Al Rasheed M.R.; Xu B.; Molecular Alterations in Thyroid Carcinoma. Surg Pathol Clin  2019,12(4),921-930","journal-title":"Surg Pathol Clin"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"Haugen B. R.","year":"2016","unstructured":"Haugen B. R.; Alexander E. K.; Bible K. C.; Doherty G. M.; Mandel S. J.; Nikiforov Y. E.; Pacini F.; Randolph G. W.; Sawka A. M.; Schlumberger M.; Schuff K. G.; Sherman S. I.; Sosa J. A.; Steward D. L.; Tuttle R. M.; Wartofsky L.; 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid  2016,26(1),1-133","journal-title":"Thyroid"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3803\/EnM.2016.31.3.392","volume":"31","author":"Kim B.H.","year":"2016","unstructured":"Kim B.H.; Kim I.J.; Recent Updates on the Management of Medullary Thyroid Carcinoma. Endocrinol Metab (Seoul)  2016,31(3),392-399","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"Cabanillas M.E.","year":"2019","unstructured":"Cabanillas M.E.; Ryder M.; Jimenez C.; Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev  2019,40(6),1573-1604","journal-title":"Endocr Rev"},{"key":"ref=7","first-page":"27","volume":"4","author":"Karimi A.","year":"2015","unstructured":"Karimi A.; Majlesi M.; Rafieian-Kopaei M.; Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol  2015,4(1),27-30","journal-title":"J Nephropharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"Cooper D.S.","year":"2005","unstructured":"Cooper D.S.; Antithyroid Drugs. N Engl J Med  2005,352(9),905-917","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/MNM.0000000000000132","volume":"35","author":"Fard-Esfahani A.","year":"2014","unstructured":"Fard-Esfahani A.; Emami-Ardekani A.; Fallahi B.; Fard-Esfahani P.; Beiki D.; Hassanzadeh-Rad A.; Eftekhari M.; Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nucl Med Commun  2014,35(8),808-817","journal-title":"Nucl Med Commun"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"Wirth L.J.","year":"2020","unstructured":"Wirth L.J.; Sherman E.; Robinson B.; Solomon B.; Kang H.; Lorch J.; Worden F.; Brose M.; Patel J.; Leboulleux S.; Godbert Y.; Barlesi F.; Morris J.C.; Owonikoko T.K.; Tan D.S.W.; Gautschi O.; Weiss J.; de la Fouchardi\u00e8re C.; Burkard M.E.; Laskin J.; Taylor M.H.; Kroiss M.; Medioni J.; Goldman J.W.; Bauer T.M.; Levy B.; Zhu V.W.; Lakhani N.; Moreno V.; Ebata K.; Nguyen M.; Heirich D.; Zhu E.Y.; Huang X.; Yang L.; Kherani J.; Rothenberg S.M.; Drilon A.; Subbiah V.; Shah M.H.; Cabanillas M.E.; Efficacy of selpercatinib in RET -altered thyroid cancers. N Engl J Med  2020,383(9),825-835","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"Schlumberger M.","year":"2015","unstructured":"Schlumberger M.; Tahara M.; Wirth L.J.; Robinson B.; Brose M.S.; Elisei R.; Habra M.A.; Newbold K.; Shah M.H.; Hoff A.O.; Gianoukakis A.G.; Kiyota N.; Taylor M.H.; Kim S.B.; Krzyzanowska M.K.; Dutcus C.E.; de las Heras B.; Zhu J.; Sherman S.I.; Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med  2015,372(7),621-630","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"Elisei R.","year":"2013","unstructured":"Elisei R.; Schlumberger M.J.; M\u00fcller S.P.; Sch\u00f6ffski P.; Brose M.S.; Shah M.H.; Licitra L.; Jarzab B.; Medvedev V.; Kreissl M.C.; Niederle B.; Cohen E.E.W.; Wirth L.J.; Ali H.; Hessel C.; Yaron Y.; Ball D.; Nelkin B.; Sherman S.I.; Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol  2013,31(29),3639-3646","journal-title":"J Clin Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","volume":"31","author":"Resteghini C.","year":"2017","unstructured":"Resteghini C.; Cavalieri S.; Galbiati D.; Granata R.; Alfieri S.; Bergamini C.; Bossi P.; Licitra L.; Locati L.D.; Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab  2017,31(3),349-361","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","volume":"13","author":"Leboulleux S.","year":"2012","unstructured":"Leboulleux S.; Bastholt L.; Krause T.; de la Fouchardiere C.; Tennvall J.; Awada A.; G\u00f3mez J.M.; Bonichon F.; Leenhardt L.; Soufflet C.; Licour M.; Schlumberger M.J.; Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol  2012,13(9),897-905","journal-title":"Lancet Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.3389\/fphar.2020.00891","volume":"11","author":"Jin Y.","year":"2020","unstructured":"Jin Y.; Xu Z.; Yan H.; He Q.; Yang X.; Luo P.; A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Front Pharmacol  2020,11,891","journal-title":"Front Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3322\/caac.21184","volume":"63","author":"Dy G.K.","year":"2013","unstructured":"Dy G.K.; Adjei A.A.; Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin  2013,63(4),249-279","journal-title":"CA Cancer J Clin"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"Cella D.","year":"2002","unstructured":"Cella D.; Lai J.; Chang C.H.; Peterman A.; Slavin M.; Fatigue in cancer patients compared with fatigue in the general United States population. Cancer  2002,94(2),528-538","journal-title":"Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1002\/jcp.27442","volume":"234","author":"Farhood B.","year":"2019","unstructured":"Farhood B.; Mortezaee K.; Goradel N.H.; Khanlarkhani N.; Salehi E.; Nashtaei M.S.; Najafi M.; Sahebkar A.; Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy. J Cell Physiol  2019,234(5),5728-5740","journal-title":"J Cell Physiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.pmrj.2010.03.024","volume":"2","author":"Mitchell S.A.","year":"2010","unstructured":"Mitchell S.A.; Cancer-related fatigue: State of the science. PM R  2010,2(5),364-383","journal-title":"PM R"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cncr.31790","volume":"125","author":"Bower J.E.","year":"2019","unstructured":"Bower J.E.; The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms. Cancer  2019,125(3),353-364","journal-title":"Cancer"},{"key":"ref=21","first-page":"12","volume":"9","author":"Esmail A.","year":"2019","unstructured":"Esmail A.; Chemical Constituents and Pharmacological Effects of Lithospermum. J Pharm  2019,9(8),12-21","journal-title":"J Pharm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.6116\/kjh.2013.28.2.67","volume":"28","author":"Choi S.B.","year":"2013","unstructured":"Choi S.B.; Bae G.S.; Jo I.J.; Park K-C.; Seo S-H.; Kim D-G.; Shin J-Y.; Gwak T-S.; Lee J-H.; Lee G-S.; Park S-J.; Song H-J.; The anti-inflammatory effect of Lithospermum Erythrorhizon on lipopolysaccharide - induced inflammatory response in RAW 264.7 cells. Korea J Herbol  2013,28(2),67-73","journal-title":"Korea J Herbol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1055\/s-0033-1350934","volume":"79","author":"And\u00fajar I.","year":"2013","unstructured":"And\u00fajar I.; R\u00edos J.; Giner R.; Recio M.; Pharmacological properties of shikonin - a review of literature since 2002. Planta Med  2013,79(18),1685-1697","journal-title":"Planta Med"},{"key":"ref=24","first-page":"1363","volume":"13","author":"Chen L.","year":"2018","unstructured":"Chen L.; Ke C.; Jing Y.; Anti-inflammatory mechanism research of Radix Arnebiae and its preparations. World Chinese Medicine  2018,13(6),1363-1367","journal-title":"World Chinese Medicine"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0040-4039(00)71917-4","volume":"16","author":"Wagner H.","year":"1975","unstructured":"Wagner H.; Wittmann D.; Sch\u00e4fer W.; Zur chemischen struktur der lithosperms\u00e4ure aus lithospermum officinale L. Tetrahedron Lett  1975,16(8),547-550","journal-title":"Tetrahedron Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2478\/s11756-006-0077-x","volume":"61","author":"Haghbeen K.","year":"2006","unstructured":"Haghbeen K.; Mozaffarian V.; Ghaffari F.; Pourazeezi E.; Saraji M.; Joupari M.D.; Lithospermum officinale callus produces shikalkin. Biologia (Bratisl)  2006,61(4),463-467","journal-title":"Biologia (Bratisl)"},{"key":"ref=27","first-page":"212","volume":"339","author":"Wagner H.","year":"1963","unstructured":"Wagner H.; Koenig H.; Isolation of a 6,9,12,15n-octadecatetraenoic acid from the fruits of Lithospermum officinale L. Biochem Z  1963,339(3),212-218","journal-title":"Biochem Z"},{"key":"ref=28","first-page":"36","volume":"24","author":"Zhao X.","year":"2008","unstructured":"Zhao X.; Wang G.; Fei H.; Study on the extraction and anti-inflammatory effect of the active components of Lithospermum officinale. Pharmacol Clin Chinese Trad Herb  2008,24(4),36-38","journal-title":"Pharmacol Clin Chinese Trad Herb"},{"key":"ref=29","first-page":"6","volume":"34","author":"Feng Ge","year":"2003","unstructured":"Feng Ge; Wang Xiao-dong; Wang Yu-chun; Advances in studies on medicinal Radix Arnebiae Seu Lithospermi. Chinese Trad Herb Drugs  2003,34(9),6-9","journal-title":"Chinese Trad Herb Drugs"},{"key":"ref=30","first-page":"2026","volume":"53","author":"Min C.","year":"2018","unstructured":"Min C.; Jun T.; Li S.; Recent advances in the research on pharmacological actions and quantitative analyses of naphthoquinones in Chinese medicinal herb \u201cZicao\u201d. Yao Xue Xue Bao  2018,53(12),2026-2039","journal-title":"Yao Xue Xue Bao"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.12659\/MSM.908381","volume":"24","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Sun B.; Huang Z.; Zhao D.W.; Zeng Q.; Shikonin inhibites migration and invasion of thyroid cancer cells by downregulating DNMT1. Med Sci Monit  2018,24,661-670","journal-title":"Med Sci Monit"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"E1909","DOI":"10.1210\/jc.2013-2583","volume":"98","author":"Yang Q.","year":"2013","unstructured":"Yang Q.; Ji M.; Guan H.; Shi B.; Hou P.; Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J Clin Endocrinol Metab  2013,98(12),E1909-E1917","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=33","first-page":"17428","volume":"9","author":"Gu M.","year":"2016","unstructured":"Gu M.; Li X.; Tang X.; Effect of autophagy on the shikonin induced apoptosis of human medullary thyroid carcinoma TT cells. Int J Clin Exp Med  2016,9(9),17428-17434","journal-title":"Int J Clin Exp Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.3892\/mmr.2016.4967","volume":"13","author":"Tang X.","year":"2016","unstructured":"Tang X.; Zhang C.; Wei J.; Fang Y.; Zhao R.; Yu J.; Apoptosis is induced by shikonin through the mitochondrial signaling pathway. Mol Med Rep  2016,13(4),3668-3674","journal-title":"Mol Med Rep"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e52706","DOI":"10.1371\/journal.pone.0052706","volume":"8","author":"Wu H.","year":"2013","unstructured":"Wu H.; Xie J.; Pan Q.; Wang B.; Hu D.; Hu X.; Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PLoS One  2013,8(1),e52706","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.5487\/TR.2015.31.4.403","volume":"31","author":"Han C.T.","year":"2015","unstructured":"Han C.T.; Kim M.J.; Moon S.H.; Jeon Y.R.; Hwang J.S.; Nam C.; Park C.W.; Lee S.H.; Na J.B.; Park C.S.; Park H.W.; Lee J.M.; Jang H.S.; Park S.H.; Han K.G.; Choi Y.W.; Lee H.Y.; Kang J.K.; Acute and 28-day subacute toxicity studies of hexane extracts of the roots of lithospermum erythrorhizon in sprague-dawley rats. Toxicol Res  2015,31(4),403-414","journal-title":"Toxicol Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5487\/TR.2015.31.1.077","volume":"31","author":"Nam C.","year":"2015","unstructured":"Nam C.; Hwang J.S.; Kim M.J.; Choi Y.W.; Han K.G.; Kang J.K.; Single- and repeat-dose oral toxicity studies of lithospermum erythrorhizon extract in dogs. Toxicol Res  2015,31(1),77-88","journal-title":"Toxicol Res"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/220678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/220678\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/220678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:58:43Z","timestamp":1746557923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/220678\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":37,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467217666230904104414","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e040923220678"}}